Navigation Links
Palatin Announces Strategic Realignment of Operations
Date:9/24/2010

>Conference Call and Webcast

Palatin's management will discuss the realignment and update on its corporate strategy on the Company's fourth quarter and full year 2010 financial results conference call scheduled for Monday, September 27, 2010 at 10:00 a.m. ET.  Call-in and webcast information are listed on Palatin's website at www.Palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc. such as statements about potential actions by regulatory agencies including the U.S. Food and Drug Administration (FDA), initiation of clinical trials, ability to obtain additional financing, proposed indications for bremelanotide and PL-3994, timing, duration, cost and results of proposed clinical trials with bremelanotide and PL-3994, and regulatory plans with bremelanotide and PL-3994, as well as statements about the effect and cost of realignment and restructuring and effect of the reverse stock split, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to th
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
2. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
3. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
5. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
6. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
7. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
8. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
9. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
10. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
11. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... 22, 2014 GenomeDx Biosciences today announced that ... Classifier, a genomic test for prostate cancer, was able ... managed by radical prostatectomy without adjuvant therapy. Although rapid ... uncommon, using tumor genomics to identify these men who ... an important advance. The study has been published ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... of HER1, HER2 and HER3 Assays to Provide Unique ... Facilitate Development of Personalized Cancer Therapies, SOUTH SAN ... ) today announced that the company,s HER1,and HER3 Quantitative ... on Monogram,s VeraTag(TM) platform, the HER1 and,HER3 assays provide ...
... Meeting of Shareholders to be Reconvened on May 29, ... Therapeutics,Corporation (Nasdaq: UTHR ) (the Company) held its ... 2008. The Company,s,shareholders voted to approve the election of ... directors with terms expiring in 2011. The,Company,s shareholders also ...
... IRVINE, Calif., May 1 Edwards Lifesciences,Corporation (NYSE: ... and technologies to,treat advanced cardiovascular disease, will host ... 2008 beginning at 10:00 a.m. PT (1:00 pm,ET) ... A live webcast of the meeting will be ...
Cached Biology Technology:HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 2United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 3Edwards Lifesciences to Webcast Annual Stockholders Meeting 2
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
(Date:12/17/2014)... DUBLIN , Dec. 15, 2014 Research ... announced the addition of the "Samsung Galaxy ... Analysis" report to their offering. ... on a totally different sensing technology than the ... a fingerprint sensor in its product. ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Scientists at the National Physical Laboratory (NPL) have ... that provides structural support to cells to aid growth ... regenerative medicine. The extracellular matrix (ECM) provides the ... all biological tissues. It is a complex nano-to-microscale structure ...
... be coming soon to an ocean near you. Sensorbots ... to open a new chapter in the notoriously challenging ... devices are being designed and developed in the laboratory ... of the Center for Biosignatures Discovery Automation at Arizona ...
... hatcheries on salmon is so profound that in just one ... prosper in the hatchery environment, at the cost of their ... These findings, published this week in Proceedings of the ... and natural selection that surprised researchers. They confirmed that ...
Cached Biology News:Sensing the deep ocean 2Sensing the deep ocean 3Sensing the deep ocean 4Sensing the deep ocean 5Evolution at warp speed: Hatcheries change salmon genetics after a single generation 2Evolution at warp speed: Hatcheries change salmon genetics after a single generation 3